Novo Nordisk files for label expansion for insulin Fiasp

|About: Novo Nordisk A/S (NVO)|By:, SA News Editor

Novo Nordisk (NYSE:NVO) has filed supplemental marketing applications in the U.S. and Europe seeking approval for fast-acting Fiasp (insulin aspart injection) 100 u/mL in children and adolescents with type 1 diabetes. Fiasp is currently approved for adults.

Subscribe for full text news in your inbox